Landos Biopharma Stock Buy Hold or Sell Recommendation
LABP Stock | USD 22.18 0.03 0.14% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Landos Biopharma is 'Hold'. Macroaxis provides Landos Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LABP positions. The advice algorithm takes into account all of Landos Biopharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Landos Biopharma's buy or sell advice are summarized below:
Real Value 10.28 | Target Price 5 | Hype Value 24.69 | Market Value 22.18 | Naive Value 18.98 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Landos Biopharma given historical horizon and risk tolerance towards Landos Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Landos Biopharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Landos |
Execute Landos Biopharma Buy or Sell Advice
The Landos recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Landos Biopharma. Macroaxis does not own or have any residual interests in Landos Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Landos Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Hold
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Landos Biopharma Trading Alerts and Improvement Suggestions
Landos Biopharma is way too risky over 90 days horizon | |
Landos Biopharma appears to be risky and price may revert if volatility continues | |
Net Loss for the year was (21.93 M) with profit before overhead, payroll, taxes, and interest of 18 M. | |
Landos Biopharma currently holds about 55.75 M in cash with (20.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
Landos Biopharma has a poor financial position based on the latest SEC disclosures | |
Latest headline from benzinga.com: STOCKHOLDER ALERT The MA Class Action Firm Continues Investigating the Merger DOMA, LABP, FUSN, CBNK |
Landos Biopharma Returns Distribution Density
The distribution of Landos Biopharma's historical returns is an attempt to chart the uncertainty of Landos Biopharma's future price movements. The chart of the probability distribution of Landos Biopharma daily returns describes the distribution of returns around its average expected value. We use Landos Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Landos Biopharma returns is essential to provide solid investment advice for Landos Biopharma.
Mean Return | 3.49 | Value At Risk | -3.52 | Potential Upside | 8.46 | Standard Deviation | 21.42 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Landos Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Landos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Landos Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Landos Biopharma backward and forwards among themselves. Landos Biopharma's institutional investor refers to the entity that pools money to purchase Landos Biopharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Perceptive Advisors Llc | 2023-12-31 | 1.5 M | Macquarie Group Ltd | 2023-12-31 | 14.7 K | Geode Capital Management, Llc | 2023-12-31 | 12.6 K | Renaissance Technologies Corp | 2023-12-31 | 11.3 K | Acadian Asset Management Llc | 2023-12-31 | 134 | Jpmorgan Chase & Co | 2023-12-31 | 59.0 | Blackrock Inc | 2023-12-31 | 42.0 | Ubs Group Ag | 2023-12-31 | 42.0 | Wells Fargo & Co | 2023-12-31 | 10.0 | Royal Bank Of Canada | 2023-12-31 | 0.0 | Tower Research Capital Llc | 2023-12-31 | 0.0 |
Landos Biopharma Cash Flow Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 9.4M | (7.4M) | 5.9M | 28.3M | 909K | 863.6K | |
Free Cash Flow | (10.0M) | (23.1M) | (27.5M) | (45.8M) | (20.5M) | (21.5M) | |
Depreciation | 103K | 137K | 196K | 577K | 44K | 41.8K | |
Other Non Cash Items | 213K | 48K | 1.2M | 1.0M | (2.1M) | (2.0M) | |
Net Income | (13.5M) | (30.1M) | (38.4M) | (39.3M) | (21.9M) | (23.0M) | |
End Period Cash Flow | 9.8M | 2.4M | 8.3M | 36.6M | 37.5M | 39.4M |
Landos Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Landos Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Landos Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Landos stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 3.59 | |
β | Beta against NYSE Composite | -1.36 | |
σ | Overall volatility | 22.05 | |
Ir | Information ratio | 0.16 |
Landos Biopharma Volatility Alert
Landos Biopharma is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Landos Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Landos Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Landos Biopharma Fundamentals Vs Peers
Comparing Landos Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Landos Biopharma's direct or indirect competition across all of the common fundamentals between Landos Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Landos Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Landos Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Landos Biopharma by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Landos Biopharma to competition |
Fundamentals | Landos Biopharma | Peer Average |
Return On Equity | -0.62 | -0.31 |
Return On Asset | -0.34 | -0.14 |
Current Valuation | 31.54 M | 16.62 B |
Shares Outstanding | 3.12 M | 571.82 M |
Shares Owned By Insiders | 9.91 % | 10.09 % |
Shares Owned By Institutions | 50.52 % | 39.21 % |
Number Of Shares Shorted | 4.9 K | 4.71 M |
Price To Book | 2.11 X | 9.51 X |
Price To Sales | 2.37 X | 11.42 X |
Gross Profit | 18 M | 27.38 B |
EBITDA | (22.73 M) | 3.9 B |
Net Income | (21.93 M) | 570.98 M |
Cash And Equivalents | 55.75 M | 2.7 B |
Cash Per Share | 1.38 X | 5.01 X |
Total Debt | 27 K | 5.32 B |
Current Ratio | 8.91 X | 2.16 X |
Book Value Per Share | 10.20 X | 1.93 K |
Cash Flow From Operations | (20.48 M) | 971.22 M |
Short Ratio | 0.11 X | 4.00 X |
Earnings Per Share | (3.50) X | 3.12 X |
Target Price | 12.71 | |
Number Of Employees | 19 | 18.84 K |
Beta | 0.15 | -0.15 |
Market Capitalization | 69.09 M | 19.03 B |
Total Asset | 38.04 M | 29.47 B |
Retained Earnings | (155.36 M) | 9.33 B |
Working Capital | 31.79 M | 1.48 B |
Net Asset | 38.04 M |
Note: Acquisition by Gregory Oakes of 1677251 shares of Landos Biopharma at 0.79 subject to Rule 16b-3 [view details]
Landos Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Landos . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Landos Biopharma Buy or Sell Advice
When is the right time to buy or sell Landos Biopharma? Buying financial instruments such as Landos Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.7M | 2.7M | 4.9M | 2.7M | Total Assets | 92.9M | 45.3M | 38.0M | 47.6M |
Use Investing Ideas to Build Portfolios
In addition to having Landos Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Air Thematic Idea Now
Air
Companies specializing in air services and air delivery. The Air theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Air Theme or any other thematic opportunities.
View All Next | Launch |
Check out Landos Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Landos Stock, please use our How to Invest in Landos Biopharma guide.Note that the Landos Biopharma information on this page should be used as a complementary analysis to other Landos Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Landos Stock analysis
When running Landos Biopharma's price analysis, check to measure Landos Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Landos Biopharma is operating at the current time. Most of Landos Biopharma's value examination focuses on studying past and present price action to predict the probability of Landos Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Landos Biopharma's price. Additionally, you may evaluate how the addition of Landos Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Landos Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Landos Biopharma. If investors know Landos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Landos Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Landos Biopharma is measured differently than its book value, which is the value of Landos that is recorded on the company's balance sheet. Investors also form their own opinion of Landos Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Landos Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Landos Biopharma's market value can be influenced by many factors that don't directly affect Landos Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Landos Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Landos Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Landos Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.